Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Lerociclib. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDK4 known ✓ | P11802 | 16/20 | 0.98 |
| ▸ | CDK6 known ✓ | Q00534 | 3/20 | 0.98 |
| ▸ | FLT3 known ✓ | P36888 | 1/20 | 0.98 |
| ▸ | CDK2 | P24941 | 20/20 | 0.98 |
| ▸ | CCND1 | P24385 | 16/20 | 0.98 |
| ▸ | CCND3 | P30281 | 3/20 | 0.98 |
| ▸ | CCNT1 | O60563 | 2/20 | 0.98 |
| ▸ | CDK9 | P50750 | 2/20 | 0.98 |
| ▸ | TTK | P33981 | 1/20 | 0.98 |
| ▸ | CCNH | P51946 | 1/20 | 0.98 |
| ▸ | NEK10 | Q6ZWH5 | 1/20 | 0.98 |
| ▸ | ULK2 | Q8IYT8 | 1/20 | 0.98 |
| ▸ | NUAK2 | Q9H093 | 1/20 | 0.98 |
| ▸ | CCNE1 | P24864 | 9/20 | 0.97 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Lerociclib SCHEMBL29409994 | 1.00 | CDK2 (0.98) | CDK2CDK4CCND1CCND3CDK6 | |
| Lerociclib SCHEMBL29409995 | 1.00 | CDK2 (0.98) | CDK2CDK4CCND1CCND3CDK6 | |
| Lerociclib SCHEMBL16036885 | 0.99 | CDK2 (1.00) | CDK2CDK4CCND1CCND3CDK6 | |
| Lerociclib SCHEMBL22832157 | 0.99 | CDK2 (1.00) | CDK2CDK4CCND1CCND3CDK6 | |
| Lerociclib SCHEMBL30175009 | 0.99 | CDK2 (1.00) | CDK2CDK4CCND1CCND3CDK6 | |
| SCHEMBL15249273 | 0.98 | CDK2 (1.00) | CDK2CDK4CCND1CCND3CDK6 | |
| SCHEMBL24413774 | 0.92 | CDK2 (0.85) | CDK2CDK4CCND1CCND3CDK6 | |
| SCHEMBL20980212 | 0.91 | CDK2 (0.87) | CDK2CDK4CCND1CCND3CDK6 | |
| Trilaciclib SCHEMBL29375833 | 0.91 | CDK2 (0.98) | CDK2CDK4CCND1CCND3CDK6 | |
| Trilaciclib SCHEMBL29514690 | 0.91 | CDK2 (0.98) | CDK2CDK4CCND1CCND3CDK6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4218820-A2 | COMBINATION THERAPIES FOR THE TREATMENT OF BREAST CANCER | Eisai R&D Management Co., Ltd. (JP) | 2023-08-02 | — | — | EP | claimed |
| US-12295955-B2 | TTP phosphorylation for the identification of personalized medicines | KING FAISAL SPECIALIST HOSPITAL & RESEARCH CENTRE (SA) | 2025-05-13 | — | — | US | disclosed |
| US-20240390406-A1 | PHOSPHORYLATED TRISTETRAPROLIN AS A BIOMARKER AND THERAPEUTIC TARGET FOR ANTIAGING DRUGS | KING FAISAL SPECIALIST HOSPITAL & RESEARCH CENTRE (SA) | 2024-11-28 | — | — | US | disclosed |
| EP-4467978-A1 | PHOSPHORYLATED TRISTETRAPROLIN AS A BIOMARKER AND THERAPEUTIC TARGET FOR ANTI-AGING DRUGS | King Faisal Specialist Hospital & Research Centre (SA) | 2024-11-27 | — | — | EP | disclosed |
| EP-4353231-A1 | COMPOUND AND METHOD FOR TREATING CHEMOTHERAPY-ASSOCIATED GASTROINTESTINAL SIDE EFFECTS | OnQuality Pharmaceuticals China Ltd. (CN) | 2024-04-17 | — | — | EP | disclosed |
| US-20230310437-A1 | TTP PHOSPHORYLATION FOR THE IDENTIFICATION OF PERSONALIZED MEDICINES | KING FAISAL SPECIALIST HOSPITAL & RESEARCH CENTRE (SA) | 2023-10-05 | — | — | US | disclosed |
| EP-4218820-A2 | COMBINATION THERAPIES FOR THE TREATMENT OF BREAST CANCER | Eisai R&D Management Co., Ltd. (JP) | 2023-08-02 | — | — | EP | disclosed |
| US-11648251-B2 | TTP phosphorylation as a biomarker in targeted therapy | KING FAISAL SPECIALIST HOSPITAL & RESEARCH CENTRE (SA) | 2023-05-16 | — | — | US | disclosed |
| EP-3595725-B1 | COMBINATION THERAPIES FOR THE TREATMENT OF BREAST CANCER | EISAI R&D MAN CO LTD (JP) | 2023-05-03 | — | — | EP | disclosed |
| EP-4121111-A1 | METHODS AND COMPOSITIONS FOR TREATING INFLAMMATORY AND FIBROTIC PULMONARY DISORDERS | University of Houston System (US) | 2023-01-25 | — | — | EP | disclosed |
| US-11083722-B2 | Combination therapies for the treatment of breast cancer | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2021-08-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11083722-B2 | Combination therapies for the treatment of breast cancer | CDK4, CDK6, CDKL4 | CDK4 1/4885CDK6 2/4885FLT3 2749/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.